Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $18.4 million.

  • RedHill Biopharma's Liabilities and Shareholders Equity fell 1656.83% to $18.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $81.5 million, marking a year-over-year decrease of 4135.03%. This contributed to the annual value of $18.0 million for FY2024, which is 2171.22% down from last year.
  • Latest data reveals that RedHill Biopharma reported Liabilities and Shareholders Equity of $18.4 million as of Q2 2025, which was down 1656.83% from $18.0 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Liabilities and Shareholders Equity ranged from a high of $220.1 million in Q1 2021 and a low of $18.0 million during Q4 2024
  • In the last 5 years, RedHill Biopharma's Liabilities and Shareholders Equity had a median value of $158.0 million in 2022 and averaged $115.6 million.
  • As far as peak fluctuations go, RedHill Biopharma's Liabilities and Shareholders Equity surged by 5341.72% in 2021, and later plummeted by 8549.32% in 2023.
  • Quarter analysis of 5 years shows RedHill Biopharma's Liabilities and Shareholders Equity stood at $181.2 million in 2021, then fell by 12.32% to $158.9 million in 2022, then crashed by 85.49% to $23.0 million in 2023, then fell by 21.71% to $18.0 million in 2024, then increased by 1.84% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q2 2025, $18.0 million for Q4 2024, and $22.0 million during Q2 2024.